Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Inotiv, Inc.

Get SEC filing alerts via email and in your feed for Inotiv, Inc.

NOTV

Inotiv, Inc.

About Inotiv, Inc.

Inotiv is a contract research organization providing nonclinical drug discovery, safety assessment, and analytical services to pharmaceutical, biotech, and medical device industries. It offers research models, laboratory animals, diets, and specialized testing services to support early-stage research, preclinical development, and regulatory submissions. With a focus on quality, animal welfare, and regulatory compliance, Inotiv enables clients to accelerate drug development and reduce costs.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Inotiv, Inc.

1
1
Inotiv, Inc. Inotiv Reports $117.7 Million Revenue and $32.5 Million Net Loss for Q1 2026

Via official filing (AI summary) | 24 days ago | 0 comments

2
1
Inotiv, Inc. Inotiv Reports $120.9 Million Revenue with Increased Service Revenue and Consolidated Net Loss

Via official filing (AI summary) | 4 months ago | 0 comments

3
1
Inotiv, Inc. Inotiv Reports Revenue Increase to $513 Million, Operating Loss Improves

Via official filing (AI summary) | 6 months ago | 0 comments

4
1
Inotiv, Inc. Inotiv Reports $130.7 Million Revenue with 23.5% Growth, Faces Net Loss of $17.6 Million

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Inotiv, Inc. Inotiv Reports $124.3 Million Revenue with Improved Net Loss for Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Inotiv, Inc. Inotiv Reports $27.6 Million Net Loss and 11.5% Revenue Decline for December 2024

Via official filing (AI summary) | over 1 year ago | 0 comments